Concord Biotech Ltd. (CONCORDBIO) Price & Analysis

Compare

2 Followers

CONCORDBIO Stock Chart & Stats

₹1362.65

₹62.10(2.74%)

At close: Jan 09 4:00 PM EST

₹1362.65

₹62.10(2.74%)

Day’s Range― - ―

52-Week Range₹1,334.50 - ₹2,451.65

Previous CloseN/A

Volume295.44K

Average Volume (3M)12.81K

Market Cap

₹144.28B

Enterprise Value₹209.52B

Total Cash (Recent Filing)₹3.18B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)44.5

Beta1.01

Next Earnings

Feb 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.77%

Share Statistics

EPS (TTM)6.00

Shares Outstanding104,616,200

10 Day Avg. Volume31,605

30 Day Avg. Volume12,808

Financial Highlights & Ratios

PEG Ratio2.27

Price to Book (P/B)9.60

Price to Sales (P/S)14.50

P/FCF Ratio127.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,825.00

Price Target Upside33.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Concord Biotech Ltd. News

Mycophenolate Pregnancy Registry: Key Insights for Investors

Amneal Pharma (($AMRX)), Sandoz Group Ltd (($SDZXF)), Alkem Laboratories Ltd. (($IN:ALKEM)), Concord Biotech Ltd. (($IN:CONCORDBIO)) announced an update...

2M ago

AMRX

Concord Biotech Releases Q1 2025 Financial Results

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) has issued an update. Concord Biotech Ltd. has released an investor presentation...

4M ago

CONCORDBIO FAQ

What was Concord Biotech Ltd.’s price range in the past 12 months?

Concord Biotech Ltd. lowest stock price was ₹1334.50 and its highest was ₹2451.65 in the past 12 months.

What is Concord Biotech Ltd.’s market cap?

Concord Biotech Ltd.’s market cap is ₹144.28B.

When is Concord Biotech Ltd.’s upcoming earnings report date?

Concord Biotech Ltd.’s upcoming earnings report date is Feb 05, 2026 which is in 49 days.

How were Concord Biotech Ltd.’s earnings last quarter?

Concord Biotech Ltd. released its earnings results on Nov 13, 2025. The company reported ₹6 earnings per share for the quarter, beating the consensus estimate of ₹5.3 by ₹0.7.

Is Concord Biotech Ltd. overvalued?

According to Wall Street analysts Concord Biotech Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Concord Biotech Ltd. pay dividends?

Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.77%. See more information on Concord Biotech Ltd. dividends here

What is Concord Biotech Ltd.’s EPS estimate?

Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Concord Biotech Ltd. have?

Concord Biotech Ltd. has 104,616,200 shares outstanding.

What happened to Concord Biotech Ltd.’s price movement after its last earnings report?

Concord Biotech Ltd. reported an EPS of ₹6 in its last earnings report, beating expectations of ₹5.3. Following the earnings report the stock price went down -0.571%.

Which hedge fund is a major shareholder of Concord Biotech Ltd.?

Currently, no hedge funds are holding shares in IN:CONCORDBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Concord Biotech Ltd.

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Ltd. (CONCORDBIO) Earnings & Revenues

Historic Earnings Reports

CONCORDBIO Stock 12 Month Forecast

Average Price Target

₹1,825.00

▲(33.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1520":"₹1,520","2175":"₹2,175","1683.75":"₹1,683.8","1847.5":"₹1,847.5","2011.25":"₹2,011.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.82K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1520,1683.75,1847.5,2011.25,2175],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1632.5,1647.3076923076924,1662.1153846153845,1676.923076923077,1691.7307692307693,1706.5384615384614,1721.3461538461538,1736.1538461538462,1750.9615384615386,1765.7692307692307,1780.576923076923,1795.3846153846155,1810.1923076923076,{"y":1825,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1632.5,1647.3076923076924,1662.1153846153845,1676.923076923077,1691.7307692307693,1706.5384615384614,1721.3461538461538,1736.1538461538462,1750.9615384615386,1765.7692307692307,1780.576923076923,1795.3846153846155,1810.1923076923076,{"y":1825,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1632.5,1647.3076923076924,1662.1153846153845,1676.923076923077,1691.7307692307693,1706.5384615384614,1721.3461538461538,1736.1538461538462,1750.9615384615386,1765.7692307692307,1780.576923076923,1795.3846153846155,1810.1923076923076,{"y":1825,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1521.21,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1592.66,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1725.86,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1966.13,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1824.98,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2174.7,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2174.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2135.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2158.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1785.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1728.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1674.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1632.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >